Physician profile
Cameron Howell
NPI 1033876628
$1,980.90
in general payments reported to CMS, 2019-2025
27 companies · $666 in 2025
The $666 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,315 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.39 | 2024-2025 | |
| Novo Nordisk INC | $365.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $196.62 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $169.89 | 2024-2025 | |
| Glaxosmithkline, LLC. | $128.69 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.74 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $97.36 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $62.41 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.53 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $42.95 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $38.70 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $30.17 | 2025 | Korlym |
| Scilex Pharmaceuticals INC. | $24.86 | 2025 | |
| Insulet Corporation | $22.68 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $22.55 | 2024 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $22.02 | 2024 | Yupelri |
| Astellas Pharma US INC | $21.84 | 2025 | Veozah |
| Almatica Pharma LLC | $21.38 | 2024 | Loreev Xr |
| Bausch Health US, LLC | $21.01 | 2024 | Aplenzin, Wellbutrin |
| Corium, LLC | $20.93 | 2024 | Azstarys |
| Abbott Laboratories | $20.14 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $19.13 | 2024 | Otezla, Repatha |
| Ironwood Pharmaceuticals, INC | $17.58 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.00 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $16.02 | 2025 | Gardasil 9, Capvaxive |
| Azurity Pharmaceuticals, INC. | $15.77 | 2024 | Horizant |
| Bayer Healthcare Pharmaceuticals INC. | $15.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.